Chongqing Traditional Chinese Medicine Hospital
12
4
4
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
25%
3 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer
Role: collaborator
Construction and Clinical Validation Study of a Prediction Model for Depression After Ischemic Stroke
Role: collaborator
Shenbai Granules for Preventing Malignant Transformation of High-risk Colorectal Adenomas
Role: collaborator
HDAC Inhibitor Combination with Chemoimmunotherapy in the Neoadjuvant Treatment of PMMR Locally Advanced Colon Cancer
Role: collaborator
Pogejiuxin Decoction Combination of Conventional Western Medicine for the Treatment of Heart Failure with Preserved Ejection Fraction
Role: lead
Effect of Glycopyrronium in Combination With Tropisetron in Anti-postoperative Nausea and Vomiting
Role: collaborator
The Effect of Lavender Essential Oil for Delirium in Elderly Intensive Care Unit Patients: Study Protocol
Role: lead
Bloodletting Puncture in the Treatment of Acute Ischemic Stroke
Role: lead
The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects
Role: collaborator
Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS)
Role: collaborator
The Study of Jian Pi Yi Shen Hua Tan Granules in Cognitive Impairment After Acute Cerebral Infarction
Role: collaborator
Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study
Role: collaborator
All 12 trials loaded